Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety
of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be
assessed vs. a parallel placebo group.
Phase:
Phase 2
Details
Lead Sponsor:
Palatin Technologies
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer